Catalyst
Monitor further data releases from the Phase III trials and any regulatory submissions or approvals.
Date
June 2, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.